Early Detection
415 articles
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Pancreatic Cancer Exceptional Responders and the Immune System Link
Dr. Vinod Balachandran looks at the immune system of exceptional responders–patients who respond extremely well to chemotherapy–for treatment clues.
Combination Delivers a Dual Punch to Pancreatic Cell Growth
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.
Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer Patients
Dr. Michael Pishvaian explains how platinum-based therapy can improve the survival of pancreatic cancer patients with a specific mutation.
CAR T Cell Trial Targets Mesothelin
In an immunotherapy clinical trial, Dr. Mark O’Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
For Pancreatic Cancer Patients, Pain Control Through Targeted Radiotherapy
Dr. Yaacov Lawrence is using celiac plexus radiotherapy in a clinical trials to target a source of pain for pancreatic cancer patients.
What Happens When Pancreatic Cancer Clinical Trials Fail?
Why do clinical trials fail? What about the patients on the trial? Learn more about what happens when pancreatic cancer clinical trials fail.
Taking a Systems Biology Approach to Find a New Pancreatic Cancer Target
Dr. Andrea Califano is using systems biology and cell regulators to find new targets in the search for ways to stop pancreatic cancer cells.
Inhibiting Cell Division With Alternating Electric Fields
Dr. Andrew Coveler explains how electric fields are being used to disrupt pancreatic cancer cell division, to make tumors more removable.
Targeting Mutant KRAS with Immunotherapy
Dr. Beatriz Carreno explains how her team is targeting the KRAS mutation with a pancreatic cancer vaccine to make the immune system work against cancer.
Targeting Metabolic Vulnerability
Dr. Jordan Winter looks at cell metabolism to find areas of vulnerability in pancreatic cancer cells, to find a way to create better treatments.
Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.